MarketPulse

CNS disorders

8 articles
The Motley FoolThe Motley Fool··Jeff Siegel

Three AI-Powered Healthcare Firms Positioned to Disrupt Medicine by 2030

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.
AXSMRXRXTEMCNS disordersprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Axsome Therapeutics Eyes Investor Spotlight with Back-to-Back Healthcare Conferences

Axsome Therapeutics to present at BofA Securities and RBC Capital Markets healthcare conferences in May 2026, with webcast access for remote investors.
AXSMFDA approvalinvestor conference
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Axsome Therapeutics Schedules Q1 2026 Earnings Report for May 4

Axsome Therapeutics will report first-quarter 2026 financial results on May 4, 2026, with management conference call at 8:00 a.m. ET.
AXSMfinancial resultsclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Minerva Neurosciences to Present CNS Pipeline at Stifel Forum Ahead of Key Phase 3 Trial

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.
NERVbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial
BenzingaBenzinga··Na

SciSparc's NeuroThera Labs to Acquire Majority Stake in Quantum Clinical Trials Pioneer

SciSparc's NeuroThera Labs acquires 54% of quantum clinical trials company CliniQuantum for $9.46M in stock plus $2.5M earn-out, closing by March 2026.
SPRCacquisitionclinical trials
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Praxis, Stock Rallies 320%

Perceptive Advisors doubles investment in Praxis Precision Medicines to $588M, now largest holding. Stock surges 320% amid FDA submissions and strong cash position.
PRAXFDA approvalinstitutional investment